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ABSTRACT
Background: Modifying dairy fat composition by increasing the
MUFA content is a potential strategy to reduce dietary SFA intake
for cardiovascular disease (CVD) prevention in the population.
Objectives: To determine the effects of consuming SFA-reduced,
MUFA-enriched (modified) dairy products, compared with conven-
tional dairy products (control), on the fasting cholesterol profile
(primary outcome), endothelial function assessed by flow-mediated
dilatation (FMD; key secondary outcome), and other cardiometabolic
risk markers.
Methods: A double-blind, randomized, controlled crossover 12-wk
intervention was conducted. Participants with a 1.5-fold higher
(moderate) CVD risk than the population mean replaced habitual
dairy products with study products (milk, cheese, and butter) to
achieve a high-fat, high-dairy isoenergetic daily dietary exchange
[38% of total energy intake (%TE) from fat: control (dietary target:
19%TE SFA; 11%TE MUFA) and modified (16%TE SFA; 14%TE
MUFA) diet].
Results: Fifty-four participants (57.4% men; mean ± SEM age:
52± 3 y; BMI: 25.8± 0.5 kg/m2) completed the study. The modified
diet attenuated the rise in fasting LDL cholesterol observed with
the control diet (0.03 ± 0.06 mmol/L and 0.19 ± 0.05 mmol/L,
respectively; P = 0.03). Relative to baseline, the %FMD response
increased after the modified diet (0.35% ± 0.15%), whereas a
decrease was observed after the control diet (−0.51% ± 0.15%;
P < 0.0001). In addition, fasting plasma nitrite concentrations
increased after the modified diet, yet decreased after the control
diet (0.02 ± 0.01 μmol/L and −0.03 ± 0.02 μmol/L, respectively;
P = 0.01).
Conclusions: In adults at moderate CVD risk, consumption of
a high-fat diet containing SFA-reduced, MUFA-enriched dairy
products for 12 wk showed beneficial effects on fasting LDL
cholesterol and endothelial function compared with conventional
dairy products. Our findings indicate that fatty acid modification of
dairy products may have potential as a public health strategy aimed
at CVD risk reduction. This trial was registered at clinicaltrials.gov
as NCT02089035. Am J Clin Nutr 2020;00:1–10.
Keywords: dairy fat, cardiovascular disease risk, cholesterol profile,
flow-mediated dilatation, saturated fatty acids, monounsaturated
fatty acids, vascular function, reformulation, food chain approach
Introduction
High intakes of SFAs have been associated with an increase
in LDL cholesterol concentrations (1), an established risk
factor in the development of cardiovascular diseases (CVDs)
(2). Although dairy products contribute ≤27% of total dietary
SFA intake in the UK (3), the majority of prospective studies
and meta-analyses show either a neutral or reduced risk of
CVD with increased consumption of milk and dairy products,
with the exception of butter (4). This finding may reflect the
complexity of the dairy food matrix (4), comprised of a mixture
of macronutrients, micronutrients, and other components (e.g.,
bioactive peptides), with studies indicating that consuming dairy
fat as hard cheese may provide beneficial blood lipid effects
compared with butter (5, 6).
Some meta-analyses have questioned the link between high
SFA intake and CVD risk and mortality (7, 8); however, evidence
indicates replacement of SFAs with unsaturated fatty acids
(FAs) is beneficial (9, 10). Interventional and observational data
have shown that substitution of dietary SFAs with MUFAs
(11) or PUFAs (11–14) is linked to reductions in CVD risk
biomarkers and events. Partial replacement of SFAs in milk fat
with unsaturated FAs, primarily in the form of cis-MUFAs, can
be achieved by supplementing the dairy cow diet with plant
Am J Clin Nutr 2020;00:1–10. Printed in USA. Copyright © The Author(s) 2020. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium,
provided the original work is properly cited. 1
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oils or oil seeds (15). This innovative animal nutrition–based
reformulation strategy could limit the entry of SFAs into the food
chain, without removing the beneficial aspects of dairy product
consumption (16, 17). Although evidence is insufficient to draw
firm conclusions, FA-modified dairy foods (primarily butter)
have the potential to beneficially affect established cholesterol-
based markers of CVD risk, relative to conventional dairy
products (18).
Since dairy products are complex in nature and CVD is
multifactorial, there is an urgent need to consider both established
lipid biomarkers and novel risk factors, including endothelial
function, arterial stiffness, and inflammatory markers, when
investigating the impact of FA-modified dairy food consumption
(16). In particular, measures of endothelial function provide
independent prognostic data on future cardiovascular events
and flow-mediated dilatation (FMD) is regarded as the gold-
standard technique for the assessment of endothelial-dependent
vasodilation and a surrogate measure of endothelial NO
production (19, 20).
To address this knowledge gap, we investigated the impact of
a high-fat, high-dairy diet incorporating SFA-reduced, MUFA-
enriched dairy products, modified via a food chain approach, on
established and novel CVD risk markers, compared with dairy
foods with an FA profile typical of conventional retail products
(control), in adults at moderate CVD risk. In our proof-of-concept
study, we hypothesized that consumption of the modified dairy
products for 12 wk would improve fasting total cholesterol (TC;
composed of LDL cholesterol and HDL cholesterol; primary
outcome), the %FMD response (key secondary outcome),
and other cardiometabolic risk markers (secondary outcomes),
compared with consumption of the control products.
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Methods
Subjects and study design
The REplacement of SaturatEd fat in dairy on Total cholesterol
(RESET) study (NCT02089035) was given a favorable ethical
opinion for conduct by the University of Reading Research Ethics
Committee (Ref. No.: 13/43) and carried out in accordance with
the principles of the Declaration of Helsinki of 1975, as revised
in 1983. Men and women (aged 25–70 y; BMI: 19–32 kg/m2)
with moderate CVD risk were recruited from Berkshire, United
Kingdom, from February 2014 to September 2015 in 3 cohorts.
To assist with participant recruitment, the study age range was
extended to 70 y from May 2014. The study was completed in
April 2016. All participants provided written informed consent.
Details of the study inclusion and exclusion criteria are reported
in Markey et al. (21). In summary, eligibility criteria included
no diagnosis of myocardial infarction, stroke, or diabetes; not
taking dietary supplements or medication for hyperlipidemia,
hypertension, hypercoagulation, or inflammatory conditions;
normal biochemistry for liver and kidney function; not pregnant
or lactating; not participating in excessive amounts of vigorous
aerobic physical activity (<3 times × 20 min/wk); and not
consuming excessive amounts of alcohol (men: <21 units/wk;
women: <14 units/wk). A total of 130 potential participants
attended a screening visit, resulting in 76 eligible for random
assignment (see Supplemental Figure 1 for the participant
flowchart). Data collected at the screening visit on fasting
serum TC, HDL cholesterol, glucose, clinic blood pressure
(BP), BMI, and family history of myocardial infarction were
used to determine eligibility, whereby a score of ≥2 CVD risk
points based on a modified Framingham risk analysis suggested
a 1.5-fold higher (moderate) CVD risk than the population
mean (11, 21, 22).
The RESET intervention was a double-blind, crossover, ran-
domized controlled proof-of-concept studywith an 8-wkwashout
period between the two 12-wk high-fat, high-dairy dietary
periods. A minimization technique stratifying by information on
age (25.0–40.0 y, 40.1–55.1 y, or 55.2–70.0 y), gender (male or
female), BMI (19.0–26.9 or 27.0–32.0 kg/m2), and fasting serum
TC (≤5.9 or ≥6.0–8.0 mmol/L) was used by a single researcher
(OM) to randomly assign eligible participants to 1 of 2 dietary
intervention groups, whereby Group 1 received the modified
diet first (Diet A) followed by the control diet (Diet B), and
vice versa for Group 2 (21). This randomization approach was
employed to minimize the imbalance of potential confounding
variables between groups with a different order of intervention
diet. Data processing and analysis of samples were completed in a
blinded fashion; biochemical analysis and raw data were labeled
by period number (i.e., visit 1, 2, 3, or 4), not by intervention
diet.
Intervention diets
Full details of the production of the SFA-reduced, MUFA-
enriched (modified) milk and dairy products have been published
elsewhere (15). Briefly, after a 4-wk supplementation of the
total mixed ration diet of multiparous Holstein-Friesian dairy
cows with ∼1 kg high-oleic sunflower oil per cow per day
(AAK Ltd.), the milk was collected for the manufacture of
ultra-high temperature (UHT) milk, cheddar cheese, and butter.
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TABLE 1 Daily energy and nutrient intakes provided by the study products in the modified and control intervention diets1
Modified Control
UHT milk Cheese Butter Total UHT milk Cheese Butter Total
Daily amount, g 340.0 45.0 25.1 — 340.0 45.0 21.5 —
Energy, MJ/d 0.79 0.69 0.76 2.24 0.75 0.76 0.65 2.16
Total fat, g/d 8.8 12.6 20.4 41.8 8.6 15.1 17.4 41.1
SFAs, g/d 4.4 6.3 10.2 20.9 5.7 10.2 11.1 27.0
MUFAs, g/d 3.6 5.0 8.1 16.7 2.1 3.5 4.4 10.0
PUFAs, g/d 0.3 0.4 0.7 1.4 0.3 0.4 0.6 1.3
TFAs, g/d 0.9 1.4 2.1 4.4 0.3 0.5 0.7 1.5
CHO, g/d 16.0 1.2 0.2 17.4 14.9 1.4 0.4 16.7
Protein, g/d 11.1 12.1 0.1 23.3 10.2 10.6 0 20.8
Calcium, mg/d 404.0 409.8 4.5 818.3 428.0 340.5 3.7 772.2
Magnesium, mg/d 37.4 13.6 0.5 51.5 39.0 13.5 0.4 52.9
Sodium, mg/d 154.8 341.9 125.9 622.6 140.7 326.5 152.1 619.3
Phosphorus, mg/d 303.3 269.5 5.9 578.7 333.5 242.4 4.9 580.8
1Adapted from Kliem et al. (15) and Markey et al. (21). Values represent daily required intakes of the 3 study products. CHO, carbohydrates; TFA, trans
fatty acid; UHT, ultra-high temperature.
Control dairy products, with an FA profile typical of those
available in supermarkets, were provided by Arla Foods UK. To
ensure that participants and investigators remained blinded to the
diets, an investigator (CCF) not involved in running the dietary
intervention was responsible for ensuring that dairy products
were provided to participants in plain packaging and were only
identifiable by a single-letter code (A or B).
A food-exchange model was designed for the RESET study,
based on the strategy for adults with moderate CVD risk de-
scribed in detail in Markey et al. (21). Participants were provided
with the study products, in blinded packaging, to take home and
were asked to consume 340 g/d of UHT milk, 45 g/d of cheddar
cheese, and 21.5 g/d (control diet) or 25.1 g/d (modified diet)
of butter. Table 1 presents the daily energy and nutrient intakes
provided by the study products. As described previously (21),
participants received individual verbal and written instructions
to incorporate the study products into their habitual diet after
the baseline clinical visit (week 0). The isoenergetic high-fat,
high-dairy daily dietary exchange [38% of total energy intake
(%TE) from total fat] was achieved by replacing dairy products,
oil/spreads, and snacks habitually consumed with either the SFA-
reduced, MUFA-enriched (modified) UHT milk, cheddar cheese,
and butter (dietary target: 16%TE SFA; 14%TE MUFA) or
matched, conventional dairy foods (control) with an FA profile
typical of retail products (19%TE SFA; 11%TE MUFA). The
2 intervention diets were equal in total exchangeable fat content
(∼41 g/d of dairy fat).
Compliance was assessed using 4-d weighed food diet diaries
(weeks 0, 12, 20, and 32), daily records of study product
consumption, and analysis of plasma phospholipid FAs (PL-
FAs) which served as a short-term biomarker of dietary fat
composition. To maintain a constant body weight, participants
were weighed every 4 wk by the investigators and any changes
≥±1 kg were addressed. At baseline, our cohort had a
mean habitual total fat intake of ∼36%TE (see Supplemental
Table 1 for reported dietary intake), which was higher than the
total fat intake estimated for the UK adult (19–64 y) population,
at 33.2%TE (3), but is comparable with total fat intake in adults
at moderate CVD risk [see the protocol article for details (21)].
Relative to the control diet, consumption of the modified diet
led to a mean decrease of SFA intake of 2.5%TE and a parallel
mean increase of MUFA intake of 3.7%TE (Supplemental
Table 1) (21). Results from the analysis of the PL-FA com-
position, which showed a significant difference between the
modified and control treatments after the two 12-wk interventions
(P ≤ 0.01), were previously presented (for a summary of the
results, see Supplemental Table 2) (21). We previously showed
that consumers generally accepted our FA-modified milk and
dairy products, when tasted in a blinded manner (23).
In addition, self-reported physical activity was assessed using
the self-administered, last 7-d version of the International
Physical Activity Questionnaire (IPAQ)-long form. A 100-mm
visual analog scale (VAS) questionnaire was also completed by
participants at the end of each 12-wk intervention period to assess
the visual appeal, smell, taste, aftertaste, and palatability of the
UHT milk, cheese, and butter.
Study visits
Study visits were conducted in a temperature-controlled
environment (22 ± 1◦C) at the Hugh Sinclair Unit of Human
Nutrition, University of Reading, during weeks 0, 12, 20,
and 32. Premenopausal women attended all visits during the
same phase of their menstrual cycles. Participants were asked
to refrain from alcohol and aerobic exercise for 24 h before
each visit and to fast overnight for 12 h after consuming a
low-fat standard meal (<1.46 MJ; <7 g total fat) that was
provided by the researchers. Participants drank only low-nitrate
mineral water (Buxton Mineral Water, Nestlé Waters UK) during
the 12-h fast and on the morning of the study visit. After a
30-min rest in the supine position, the same trained researcher
performed noninvasive vascular function measurements at all
4 visits for each study participant. Fasted venous blood samples
were then collected into lithium heparin–coated, EDTA-coated,
or serum separator blood collection tubes (VACUETTE, Greiner
Bio-One) and either kept briefly on ice (plasma samples) or
left to clot for ≥30 min at room temperature (serum samples)
before centrifugation at 1700 × g for 15 min at 4◦C. Plasma and
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serum were divided into aliquots before storage at −80◦C until
analysis.
Biochemical analyses, risk scores, and predictive equations
Serum lipids [TC, HDL cholesterol, and triacylglycerol
(TAG)], glucose, apoB, C-reactive protein, and nonesterified fatty
acids (NEFAs) were measured using an ILAB 600 autoana-
lyzer (TC, HDL cholesterol, TAG, glucose, and ultrasensitive
C-reactive protein reagents and autoanalyzer: Werfen UK Ltd.;
apoB reagent: Randox Laboratories Ltd.; NEFA reagent: Alpha
Laboratories Ltd.). The Friedewald equation was used to estimate
fasting LDL cholesterol (24). ELISA kits were used to analyze
serum insulin (Dako UK Ltd.), plasma vascular adhesion
molecule 1 (VCAM-1) and intercellular adhesion molecule 1
(ICAM-1), E-selectin, and P-selectin (R&D Systems Europe
Ltd.). Insulin resistance was estimated by HOMA-IR, whereas
insulin sensitivity was estimated with the revised quantitative
insulin sensitivity index (rQUICKI), using standard equations
(25). Measurement of plasma nitrite and nitrate was determined
by HPLC (ENO-30, EiCom Corporation) coupled with online
reduction of nitrate to nitrite, and postcolumn derivatization with
the Greiss reagent (ENO-30 Analyzer, EiCom Corporation) (26).
Mean interassay CVs were<5% for automated assays and<10%
for all other assays.
Risk scores pre- and postintervention for both diets were
calculated using the modified Framingham CVD score (11, 21).
Furthermore, postintervention changes in dietary total FA intake,
as assessed by the 4-d weighed food diet diaries, were used to
calculate the predicted change in TC and LDL cholesterol with
the use of 5 published equations (27), which included change in
FA intake of total SFAs, MUFAs, and PUFAs as summarized in
Supplemental Table 3.
NMR metabolomics
A high-throughput 1H-NMRmetabolomics platform (Nightin-
gale Health Ltd.) was used to quantify the particle size of the
subclasses of LDL and HDL, and concentrations of particles
within each subclass, as previously described (28). This article
will present the change-from-baseline () after the 2 intervention
diets for the LDL [classified by their mean diameter size as small
(18.7 nm), medium (23 nm), and large (25.5 nm)] and HDL
[classified as small (8.7 nm), medium (10.9 nm), large (12.1 nm),
and very large (14.3 nm)] concentrations according to particle
size (28).
Assessment of vascular outcomes and 24-h ambulatory BP
Before assessing the vascular function measurements, clinic
supine BP was measured on the left upper arm with the use
of a validated BP monitor (Omron MX2 Digital Automatic
Upper Arm Blood Pressure Monitor; OMRON). Endothelial
function was assessed using FMD as described elsewhere
(29). Briefly, trained researchers used a CX50 CompactX-
treme portable ultrasound system (Philips HealthCare) to deter-
mine endothelial-dependent vasodilation of the brachial artery
following defined guidelines. Electrocardiogram-gated images
were captured at 0.25 frames/s for 660 s with the use of
image-grabbing software (Vascular Research Tools 5; Medical
Imaging Applications LLC) (29). The analysis of obtained
images was performed in a blinded manner, with the use of wall-
tracking software (Vascular Research Tools 5; Medical Imaging
Applications LLC). The %FMD response was calculated as
(diametermax − diameterbaseline)/diameterbaseline × 100. For each
image, the %FMD response was assessed in triplicate, from
which the mean response was calculated. Reduced bioavailability
of NO plays a significant role in endothelial dysfunction, as
indicated by an impaired brachial artery %FMD response (19).
Preocclusion and peak artery diameter and time to peak diameter
were also determined.
The carotid intima media thickness (cIMT), defined as the
distance between the media–adventitia interface and the intima–
lumen interface, was assessed using a 12-3 linear array transducer
and CX50 ultrasound system (Philips HealthCare) on the right
and left common carotid arteries, following published guidelines
(30). Using automated edge-tracking software (QLAB, Philips),
images of the far-wall cIMT were captured when the carotid
vessel was at its widest diameter, reflecting artery expansion. The
mean of both the right and left sides was used to represent the
cIMT value (30).
Radial pulse wave analysis (PWA) and carotid-femoral pulse
wave velocity (PWV; m/s) were measured in triplicate using
a SphygmoCor (AtCor Medical), as previously described (11).
PWA determined the augmentation index, which was corrected
for a heart rate of 75 beats/min (%). The stiffness index (m/s)
and reflection index (%) were determined by digital volume
pulse (DVP; Pulse Trace PCA2, Micro Medical Ltd.), providing
measures of arterial stiffness and vascular tone, respectively (11).
Ambulatory blood pressure (ABP) and heart rate were mea-
sured using A/A grade automated oscillometric ABP monitors
(A&D Instruments Ltd.) every 30 min from 07:00 to 21:59
and every 60 min from 22:00 to 06:59 (11). Participants were
asked to wear the ABP monitors for ≥48 h before each of the
4 visits and repeat each measurement on the same selected day
of the week. Sleep times were recorded by the participants and
used to estimate mean 24-h day and night measurements. Pulse
pressure was calculated as the difference between systolic BP and
diastolic BP.
Statistical analysis
For our primary outcome (serum TC, composed of LDL
cholesterol and HDL cholesterol), a total of 54 eligible par-
ticipants were required to achieve a ∼0.3 mmol/L predicted
reduction in TC (using the Keys equation) taking into consid-
eration a difference of 4.0%TE from SFAs and a population
mean ± SD of 4.54 ± 0.5 mmol/L, 80% power, 5% significance
level, and allowing for a 15% dropout rate (31). Accounting
for dropout, 46 participants were needed to complete the study.
The same cohort size was also sufficient to detect a 1.5%
intergroup difference in the %FMD response (key secondary
outcome), with a power of 80% at P < 0.05 (32). A P value
of <0.05 was considered significant for the primary (TC)
and the key secondary (%FMD response) outcomes. Other
secondary outcome measures were fasting lipid profile (TAG,
apoB, and NEFA); HDL/LDL particle size distribution; indexes
of insulin resistance (glucose, insulin, HOMA-IR, rQUICKI);
measurements of arterial stiffness (PWA, PWV, DVP) and cIMT;
clinic BP; 24-h ABP; circulating biomarkers of endothelial
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activation and inflammation (nitrite, nitrate, VCAM-1, ICAM-1,
E-selectin, P-selectin, C-reactive protein); and CVD risk scores.
For the other secondary outcome variables, no formal sample
size calculations were performed. A P value of ≤0.01 was
chosen a priori when assessing significance for these variables to
acknowledge the issue of multiple comparisons but also to allow
identification of interesting findings (33). Results in tables are
presented as unadjusted means ± SEMs.
Statistical analyses were predominantly conducted using the
SAS 9.4 University edition statistical software (SAS Institute
Inc.). All variables were checked for normality and data were
logarithmically transformed where needed. Treatment effects
were evaluated for all primary and secondary outcomes using a
linear mixed model, with  for each 12-wk dietary intervention
(calculated by subtracting week 0 fromweek 12 values; and week
20 from week 32 values) as the dependent variable, adjusted
for fixed effects of baseline values of the assessed variable,
period, sequence, treatment, age, gender, and BMI. Fixed-effect
covariates were retained in the linear mixed model irrespective
of their degrees of significance. Participant was included as a
random effect. No period effects were observed in the model
for any outcome measure. Results from the VAS questionnaire
were analyzed using paired t tests to assess differences between
study product ratings. Baseline characteristics of participants
randomly assigned to consume the modified and control
dairy products during their first dietary exchange period (i.e.,
week 0) were assessed by independent t tests and chi-square
tests for continuous and categorical variables, respectively. Since
this is a proof-of-concept study rather than a confirmatory trial,
we chose to adopt a per-protocol analysis approach a priori
(21). This approach was taken, rather than intention-to-treat,
because the study is designed to evaluate efficacy rather than
effectiveness (34).
Results
Study participants, CVD risk score, and product rating
A total of 76 eligible participants were randomly recruited
to the intervention, 54 of whom completed both arms of the
study successfully (Supplemental Figure 1). Reasons for dropout
included: unable to comply with the intervention (n = 9); time
commitment (n = 8); and health or personal issues unrelated to
the intervention (n = 5). While undergoing the modified or the
control dietary exchange period, 7 participants withdrew from
each arm; this suggests that the diets were similar in terms of
acceptability (21). Table 2 shows baseline characteristics (at the
start of the first dietary intervention period) of the 54 participants
who completed the study. As outlined previously (21), there
were no significant differences in the baseline characteristics
of participants randomly allocated to the modified and control
dietary interventions at baseline (week 0). Inclusion of dropouts
did not affect baseline demographic characteristics.
Participant physical activity scores, based on the IPAQ
questionnaire, did not significantly differ between treatments,
relative to baseline (data not shown). The VAS questionnaire,
which assessed the visual appeal, smell, taste, aftertaste, and
palatability of the 3 dairy products after the modified and
control diets, showed no significant treatment effect (data not
shown).
TABLE 2 Characteristics of study participants at the beginning of the first
dietary exchange period1
Characteristics
Overall group
(n = 54)
Modified
(n = 24)
Control
(n = 30)
Age, y 52 ± 3 51 ± 3 52 ± 2
Sex
Men 31 (57.4) 15 (62.5) 16 (53.3)
Women 23 (42.6) 9 (37.5) 14 (46.7)
BMI, kg/m2 25.8 ± 0.5 25.8 ± 0.7 25.0 ± 0.6
Waist circumference, cm 89.8 ± 1.4 90.2 ± 2.2 86.7 ± 1.9
Clinic SBP, mm Hg 123 ± 2 122 ± 2 119 ± 2
Clinic DBP, mm Hg 74 ± 1 74 ± 2 71 ± 1
Fasting serum biomarkers
TC, mmol/L 5.49 ± 0.12 5.45 ± 0.18 5.60 ± 0.20
LDL-C, mmol/L 3.47 ± 0.11 3.40 ± 0.15 3.52 ± 0.15
HDL-C, mmol/L 1.48 ± 0.04 1.49 ± 0.08 1.46 ± 0.04
Triacylglycerol, mmol/L 1.17 ± 0.06 1.22 ± 0.11 1.14 ± 0.07
Glucose, mmol/L 5.37 ± 0.11 5.46 ± 0.22 5.37 ± 0.17
Insulin, pmol/L 36.3 ± 2.8 35.3 ± 3.7 37.1 ± 4.0
HOMA-IR 1.44 ± 0.11 1.41 ± 0.15 1.46 ± 0.16
CVD risk score2 3.0 ± 0.2 2.8 ± 0.2 3.2 ± 0.3
1Adapted from Markey et al. (21). Values are mean ± SEM
or n (%). n = 54 (overall group). No significant differences between groups of
participants randomly assigned to consume the modified and control dairy
products during their first dietary exchange period were identified for any of
the baseline characteristics [independent t tests (continuous variables);
chi-square test (categorical variable)]; P > 0.05. CVD, cardiovascular disease;
DBP, diastolic blood pressure; HDL-C, HDL cholesterol; LDL-C, LDL
cholesterol; SBP, systolic blood pressure; TC, total cholesterol.
2Determined by using the REplacement of SaturatEd fat in dairy on Total
cholesterol study screening tool (21). A score of ≥2 points relates to a 50%
greater risk of CVD than the population mean.
Fasting serum lipids and biochemical analyses
Although therewas no significant in serumTCbetween diets
(P = 0.08), consumption of the modified diet had a significant
beneficial effect in terms of attenuation of the rise of the
LDL cholesterol concentration after the control diet (P = 0.03;
Figure 1, Supplemental Table 4). There was no evidence of
a difference in  in HDL cholesterol between the 2 diets. As
shown in Figure 1, there was a differential effect of the diets
on the LDL cholesterol:HDL cholesterol ratio, which decreased
significantly after the modified diet, whereas it increased after
the control diet (P = 0.04). No significant treatment effect was
observed for any other component of the lipid profile measured
or indexes of insulin sensitivity/resistance (Table 3). There was
a differential effect of the dairy fat diets on fasting plasma
nitrite concentrations, with an increase observed relative to
baseline after the modified diet and a decrease observed after
the control diet (P = 0.01; Table 4). There was no significant
effect of the diets on plasma nitrate or any of the markers
of endothelial activation or inflammation (VCAM-1, ICAM-1,
E-selectin, P-selectin, C-reactive protein; Table 4). Lastly, there
was no differential effect of treatment on the CVD risk score,
relative to baseline (data not shown).
Predictive equations of TC and LDL cholesterol
Using the 5 previously published equations summarized
by author and year of publication in Müller et al. (27),
greater changes in TC and LDL cholesterol concentrations were
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FIGURE 1  fasting cholesterol profile after 12-wk diets that in-
corporated modified and control dairy products. Values are unadjusted
means ± SEMs. n= 54. Linear mixed-model analyses were used to calculate
overall effect of treatment based on values, with adjustments made for fixed
effects of baseline values of the assessed variable, period, treatment sequence,
gender, age, and BMI. Participant was included as a random effect. The 
values after each 12-wk dietary intervention were calculated by subtracting
week 0 from week 12 values; and week 20 from week 32 values. No period
effects were observed in the model for any outcome measure. ∗P < 0.05.
HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; TC, total cholesterol;
, change-from-baseline.
predicted than the study results observed (Supplemental Table 3).
Relative to baseline values, TC concentrations after the modified
diet were predicted to increase by 3.1% (31, 35–37) or 2.7%
(38), compared with the observed 2.2%. After the control diet,
predicted increases in TC were 6.7% (31, 35, 36), 5.7% (37), and
5.3% (38), compared with the observed 5.5%. Similarly, LDL
cholesterol concentrations after the modified diet were predicted
to increase by 3.5% (35, 36), 2.3% (37), and 4% (38) relative to
baseline, whereas after the control diet, values were predicted to
increase by 7.6% (35, 36) 6.4% (37), and 8.2% (38), compared
with the observed 0.9% and 5.5% increases after themodified and
control diets, respectively.
Endothelial function, indexes of arterial stiffness, and 24-h
ABP
There was a significant treatment effect for the %FMD
response, representing the NO-mediated vasodilation, whereby
themodified diet resulted in an increase in response from baseline
(0.35 ± 0.15%), compared with a decrease after the control diet
(−0.51 ± 0.15%; P < 0.0001) (Table 4). In addition, peak artery
diameter increased in response to the modified diet, whereas it
decreased after the control diet (P= 0.02). Time to peak diameter
was found to decrease after themodified diet, whereas it increased
after the control diet (P = 0.04). There was no significant
treatment effect on the preocclusion artery diameter after the
2 intervention diets, compared with baseline values (Table 4).
No differences between the 2 treatments were observed for
any of the other vascular measurements including cIMT and
arterial stiffness (augmentation index measured by PWA), PWV
and DVP (stiffness index and reflection index), and 24-h ABP
measurement (Table 4).
NMR metabolomics
There were no significant differences observed in the con-
centrations of lipoprotein particles within the LDL or HDL
subclasses after the 2 intervention diets and compared with
baseline values (Table 3).
Discussion
To our knowledge this is the first study to report the longer-
term effects of partially replacing SFAs with MUFAs in a
variety of dairy products (UHT milk, cheddar cheese, and butter,
modified by a food chain approach) on the fasting lipid profile,
endothelial function, and CVD risk biomarkers, in adults at
moderate CVD risk. We observed evidence of a significant
beneficial effect of the modified diet in attenuating the rise in
serum LDL cholesterol and lowering the LDL cholesterol:HDL
cholesterol ratio compared with the control diet. A significant
increase in the %FMD response and suggestion of an increase in
fasting nitrite (a surrogate marker of endothelial NO production)
were also evident after modified compared with the control dairy
intake.
Our study findings indicate that a high-fat, high-dairy diet
including conventional (control) dairy foods led to an increase
in LDL cholesterol concentrations (0.19 ± 0.05 mmol/L), which
was attenuated by consumption of FA-modified dairy products
(0.03 ± 0.06 mmol/L). Our data are in agreement with a review
of previously published human trials investigating the chronic
impact of FA-modified butter/dairy products, which indicated a
tendency toward a beneficial effect on the fasting cholesterol
profile (18). This finding may be associated with the impact
of dietary FAs on hepatic LDL-receptor expression and activity
(39). However, a previous study suggested that 8-wk replacement
of 3–6% of dietary SFAs with MUFAs was associated with
higher TAG content and particle size of TAG-rich lipoproteins,
which may affect LDL residence time in the circulation (40).
As suggested in an in vitro study (41), a MUFA-rich meal led
to lower competition between postprandial circulating TAG-rich
lipoproteins and LDL for uptake by the LDL-receptor, than an
SFA-rich meal. This mechanism may potentially explain higher
fasting LDL cholesterol after chronic ingestion of the control
than after the modified dairy products. Furthermore, there is
increasing evidence suggesting that dietary SFA intake may
differentially affect LDL particle subclass distribution, with a
greater preponderance of smaller, denser particles recognized
as more strongly associated with CVD outcomes than larger
particles (42). In our study, there was no significant effect on
the concentration, or distribution, of particles within the LDL
and HDL subclasses, which may be explained by the differential
cardiometabolic health effects of our dairy food sources (4) and
the relatively modest differences in SFA and MUFA composition
between the intervention products (21).
Using 5 previously published equations (31, 35–38), we
predicted greater increases in TC and LDL cholesterol con-
centrations in response to our high-fat, high-dairy diets than
the changes observed in the fasting lipid profile. Although it
should be noted that reporting mean values for the observed
and the predicted equations is associated with errors and does
not provide any conclusive information, postintervention TC
concentrations after the 2 diets were similar to those predicted
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TABLE 3 Fasting lipid profile, LDL/HDL particle size distributions, and indexes of insulin resistance at baseline (week 0/week 20) and postintervention
(week 12/week 32), and the  after consumption of the modified and control diets1
Modified Control
Baseline Post  Baseline Post  P2
Fasting lipid profile
Triacylglycerol, mmol/L 1.24 ± 0.07 1.35 ± 0.10 0.11 ± 0.07 1.18 ± 0.06 1.24 ± 0.07 0.06 ± 0.05 0.32
ApoB, g/L 1.01 ± 0.03 1.03 ± 0.03 0.02 ± 0.01 1.00 ± 0.03 1.03 ± 0.03 0.03 ± 0.01 0.47
NEFAs, μmol/L 567 ± 24 514 ± 23 − 53 ± 27 556 ± 27 515 ± 23 − 41 ± 27 0.84
Particle size distributions
LDL,3 nmol/L
Small 172 ± 4 175 ± 5 3 ± 1 169 ± 4 176 ± 4 7 ± 2 0.36
Medium 278 ± 8 282 ± 8 5 ± 2 268 ± 9 284 ± 8 16 ± 8 0.34
Large 570 ± 16 581 ± 17 11 ± 5 551 ± 18 581 ± 16 38 ± 19 0.34
HDL,4 nmol/L
Small 10,100 ± 109 10,307 ± 128 207 ± 102 10,080 ± 125 10,354 ± 117 247 ± 112 0.85
Medium 3974 ± 102 4106 ± 111 132 ± 52 4028 ± 111 4118 ± 117 87 ± 55 0.46
Large 1592 ± 106 1652 ± 106 60 ± 53 1620 ± 91 1656 ± 101 36 ± 43 0.30
Very large 229 ± 12 243 ± 14 14 ± 8 229 ± 11 238 ± 12 13 ± 7 0.33
Indexes of insulin resistance/sensitivity
Glucose, mmol/L 5.38 ± 0.10 5.32 ± 0.10 − 0.06 ± 0.07 5.40 ± 0.10 5.44 ± 0.14 0.04 ± 0.09 0.34
Insulin, pmol/L 41.3 ± 3.2 39.5 ± 2.9 − 1.9 ± 1.9 39.8 ± 3.5 47.3 ± 6.1 7.5 ± 4.5 0.09
HOMA-IR 1.66 ± 0.13 1.55 ± 0.12 − 0.11 ± 0.08 1.59 ± 0.14 1.88 ± 0.22 0.29 ± 0.12 0.08
rQUICKI 0.18 ± 0.00 0.19 ± 0.00 0.01 ± 0.00 0.18 ± 0.00 0.18 ± 0.00 0.00 ± 0.00 0.11
1Values are unadjusted means ± SEMs. n = 54. NEFA, nonesterified fatty acid; rQUICKI, revised quantitative insulin sensitivity index; ,
change-from-baseline.
2Linear mixed-model analyses were used to calculate the overall effect of treatment based on  values, with adjustments made for fixed effects of
baseline values of the assessed variable, period, treatment sequence, gender, age, and BMI. Participant was included as a random effect. The  values after
each 12-wk dietary intervention were calculated by subtracting week 0 from week 12 values; and week 20 from week 32 values. No period effects were
observed in the model for any outcome measure. P ≤ 0.01 was deemed significant. Data not normally distributed were log transformed.
3LDL particles were classified by their mean diameter size as small (18.7 nm), medium (23 nm), and large (25.5 nm) (28).
4HDL particles were classified by their mean diameter size as small (8.7 nm), medium (10.9 nm), large (12.1 nm), and very large (14.3 nm) (28).
by the equation of Clarke et al. (37), which included a coefficient
of change in dietary MUFA. Furthermore, the observed increases
in LDL cholesterol after the control diet were also slightly
lower than predicted. Differences between the predicted and
observed LDL cholesterol response after themodified and control
diets may be partly explained by the dairy food matrix (4),
because the protein and micronutrient contents of the study
products were similar across diets (15, 21). It is of note that our
intervention diets included a large quantity of butter, which has
been shown to elicit a greater fasting LDL cholesterol response
than cheese, due to its lower calcium and dairy matrix content
(4–6). Therefore, removing butter as an intervention food may
have further attenuated the increase in LDL cholesterol concen-
trations. Future investigations to explore potential mechanisms
associated with the FA-modified dairy products matrix on lipid
metabolism are required.
Interestingly, the observed attenuation in LDL cholesterol
after modified dairy consumption was found even though the
intake of dietary total trans fatty acids (TFAs) had increased,
compared with intake after the control diet (2.5%TE compared
with 1.2%TE) (21). Although it was not possible to adequately
discriminate between the participants’ intake of industrial and
ruminant TFAs (rTFAs) in our 2 diets, supplementation of
the bovine diet led to a greater proportion of rTFAs in the
modified dairy products (15). The higher TFA intake following
the modified diet exceeded the UK recommendation of 2%TE
and the current mean intake in adults (0.5%TE) (3). However,
the increased TFA intake following our modified diet did not
adversely affect fasting lipid biomarkers. This is in agreement
with a meta-analysis of randomized controlled trials (RCTs)
which found no relation between rTFA daily intake of≤4.19%TE
and CVD lipid risk biomarkers in healthy adults (43). Until
there are more definitive data on any association between rTFAs
and health, further studies should consider the supplementation
of bovines with plant oils using encapsulated technology to
protect against ruminal biohydrogenation, which may help to
limit the increase in rTFAs that we observed in our modified milk
fat (21).
Progression of endothelial dysfunction mediates an increased
CVD risk (19, 20). Our finding of a significant improvement in
%FMD response after the modified compared with the control
diet agrees with an RCT that reported an increased proportion
of SFAs in the diet from butter (50 g/d; 19%TE) over a 3-wk
period impaired the FMD response relative to 3 isoenergetic diets,
including 1 rich in MUFAs (19%TE) from canola margarine
(25 g/d) and almonds (45 g/d) (44). Our results lend support
to previous studies which found an improvement in the %FMD
response after high-MUFA diets, with the beneficial effects of
these olive oil–rich diets on endothelial function being primarily
attributed to their oleic acid and/or polyphenol content (45–47).
A meta-analysis by Inaba et al. (19) concluded that a 1% higher
%FMD response at baseline was associated with a 13% lower
risk of CVD events, after a mean 3-y follow-up. Based on the
meta-analysis (19), it is estimated that consuming our modified
diet for 12 wk would represent a 4.6% reduction in future CVD
events.
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TABLE 4 Vascular outcomes, blood pressure, endothelial and inflammatory biomarkers, and cardiovascular disease risk scores at baseline (week 0/
week 20) and postintervention (week 12/week 32), and the  after consumption of the modified and control diets1
Modified diet Control diet
Assessment Baseline Post  Baseline Post  P2
Endothelial function
%FMD 4.42 ± 0.27 4.77 ± 0.28 0.35 ± 0.15 4.68 ± 0.28 4.14 ± 0.30 − 0.51 ± 0.15 <0.0001
Preocclusion artery diameter, mm 3.61 ± 0.09 3.68 ± 0.09 0.06 ± 0.04 3.67 ± 0.10 3.63 ± 0.09 − 0.04 ± 0.04 0.08
Peak artery diameter, mm 3.77 ± 0.09 3.85 ± 0.09 0.07 ± 0.04 3.84 ± 0.10 3.77 ± 0.10 − 0.07 ± 0.04 0.02
Time to peak diameter, s 53.8 ± 1.9 53.3 ± 2.0 − 0.5 ± 1.9 53.7 ± 2.1 58.5 ± 2.2 4.5 ± 2.4 0.04
Arterial stiffness
PWA-derived AI at 75 beats/
min, %
18.9 ± 1.6 19.1 ± 1.4 0.2 ± 0.7 17.1 ± 1.4 18.5 ± 1.4 1.4 ± 0.8 0.62
PWV, m/s 7.6 ± 0.3 7.4 ± 0.2 − 0.2 ± 0.5 7.5 ± 0.2 7.8 ± 0.3 0.3 ± 0.4 0.21
DVP-derived stiffness
index, m/s
7.6 ± 0.3 7.8 ± 0.4 0.2 ± 0.4 7.9 ± 0.4 8.2 ± 0.3 0.3 ± 0.3 0.96
DVP-derived reflection
index, %
69.1 ± 1.9 70.8 ± 1.9 1.7 ± 1.9 71.2 ± 1.8 70.3 ± 1.6 − 0.9 ± 1.3 0.57
Clinic BP, mm Hg
SBP 120 ± 2 119 ± 1 − 1 ± 1 120 ± 2 119 ± 2 − 1 ± 1 0.44
DBP 70 ± 1 69 ± 1 − 1 ± 1 70 ± 1 70 ± 1 0 ± 1 0.24
Ambulatory BP, mm Hg
24-h SBP 123 ± 2 124 ± 2 1 ± 1 123 ± 2 124 ± 2 1 ± 1 0.90
24-h DBP 74 ± 1 74 ± 1 0 ± 1 74 ± 1 75 ± 1 1 ± 1 0.60
24-h PP 49 ± 1 50 ± 1 1 ± 1 49 ± 1 49 ± 1 1 ± 1 0.64
Day SBP 127 ± 2 128 ± 2 1 ± 1 127 ± 2 128 ± 2 1 ± 1 0.92
Day DBP 77 ± 1 77 ± 1 0 ± 1 77 ± 1 77 ± 1 0 ± 1 0.51
Day PP 50 ± 1 51 ± 1 1 ± 1 50 ± 1 50 ± 1 0 ± 1 0.72
Night SBP 108 ± 2 110 ± 2 2 ± 2 108 ± 2 107 ± 2 − 1 ± 1 0.15
Night DBP 63 ± 1 65 ± 1 2 ± 1 63 ± 1 64 ± 1 1 ± 1 0.29
Night PP 45 ± 1 45 ± 1 0 ± 1 44 ± 1 43 ± 1 − 1 ± 1 0.26
cIMT, mm 0.59 ± 0.02 0.59 ± 0.02 0.00 ± 0.00 0.58 ± 0.01 0.59 ± 0.02 0.01 ± 0.01 0.83
Circulating biomarkers of endothelial activation and inflammation
Nitrite, μmol/L 0.13 ± 0.02 0.15 ± 0.02 0.02 ± 0.01 0.15 ± 0.02 0.11 ± 0.02 − 0.03 ± 0.02 0.01
Nitrate, μmol/L 17.74 ± 1.60 17.25 ± 1.29 − 0.49 ± 1.49 16.96 ± 1.03 16.63 ± 1.30 − 0.33 ± 1.56 0.51
VCAM-1, ng/mL 534.9 ± 29.7 537.9 ± 29.7 3.0 ± 20.7 542.8 ± 28.9 499.9 ± 28.3 − 40.1 ± 1.7 0.08
ICAM-1, ng/mL 84.4 ± 6.6 79.2 ± 6.5 − 5.1 ± 4.3 80.3 ± 8.6 87.0 ± 8.6 6.7 ± 5.5 0.64
E-selectin, ng/mL 27.0 ± 1.9 25.2 ± 1.7 0.6 ± 0.7 24.3 ± 1.7 25.2 ± 1.9 0.8 ± 0.6 0.84
P-selectin, ng/mL 25.2 ± 1.4 26.6 ± 1.6 1.5 ± 0.7 25.9 ± 1.5 26.1 ± 1.5 0.1 ± 0.7 0.30
C-reactive protein, mg/L 2.03 ± 0.76 1.59 ± 0.32 − 0.44 ± 0.5 2.12 ± 0.60 1.75 ± 0.42 − 0.37 ± 0.62 0.51
1Values are unadjusted means ± SEMs. n = 54 (except for DVP, n = 46; FMD, n = 50; PWA, n = 50; PWV, n = 29). AI, augmentation index; BP, blood
pressure; cIMT, carotid intima media thickness; DBP, diastolic blood pressure; DVP, digital volume pulse; FMD, flow-mediated dilatation; ICAM-1,
intercellular adhesion molecule 1; PP, pulse pressure; PWA, pulse wave analysis; PWV, pulse wave velocity; SBP, systolic blood pressure; VCAM-1, vascular
adhesion molecule 1; , change-from-baseline.
2Linear mixed-model analyses were used to calculate the overall effect of treatment based on  values, with adjustments made for fixed effects of
baseline values of the assessed variable, period, treatment sequence, gender, age, and BMI. Participant was included as a random effect. The  values after
each 12-wk dietary intervention were calculated by subtracting week 0 from week 12 values; and week 20 from week 32 values. No period effects were
observed in the model for any outcome measure. For the key secondary outcome (%FMD response), P < 0.05 was deemed significant. For all other secondary
outcomes, P ≤ 0.01 was deemed significant. Data not normally distributed were log transformed.
The regulation of vascular tone and function is mediated
in part by NO bioavailability (48). Consumption of a diet
high in cis-MUFAs for 28 d has been reported to result in
higher circulating concentrations of plasma nitrates and nitrites
(NOx) relative to a SFA-rich diet or a low-fat diet enriched in
α-linolenic acid, which may reflect a beneficial impact of the
MUFA-rich diet on the activity of endothelial NO synthase
(49). In support of these data, we observed an increase in
plasma nitrite concentrations after the modified diet. It could
be speculated that FA-modified dairy product consumption im-
proved endothelial function, thus stimulating NO synthases from
endothelial tissue and increasing plasma nitrite concentrations,
as described previously in response to a polyphenol-rich olive oil
diet (47).
Strengths of our study include its long-term, double-blind,
and randomized design. We employed a food chain approach to
reduce SFAs in dairy products, which has the potential to prevent
movement of SFAs into other food chain entry points (16, 17)
and results in “clean” label products favored by consumers (50).
A potential limitation of the current study is that our participants
were at increased CVD risk and predominantly white (21), thus
reducing the generalizability of our findings across different
population groups. The implementation of high-fat, high-dairy
diets with differential FA composition meant that participants
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consumed large quantities of dairy products, which may not
reflect habitual dairy and total fat intake (21). Future confirmatory
investigations with lower, more representative dairy intakes are
warranted. Finally, our study was not powered to detect changes
in secondary outcomes; therefore, these outcomes should be
interpreted with caution.
Our proof-of-concept study is the first to our knowledge to
use an agricultural-based reformulation initiative to investigate
the impact of SFA-reduced, MUFA-enriched UHT milk, cheddar
cheese, and butter on established and novel CVD risk outcomes
and indicated that high daily consumption of these products
(∼41 g/d of dairy fat) is suggestive of a beneficial attenuation
of the rise in LDL cholesterol concentration observed with
conventional dairy products in adults at moderate CVD risk.
Our findings also indicate that nitrite concentrations and NO-
mediated endothelial-dependent vasodilation improved after the
FA-modified diet, with the increase in the %FMD response
predicted to reduce the risk of CVD events by 4.6% (19).
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